Medicus Pharma Secures Clearance for Phase 2b Teverelix Prostate Cancer Trial
Medicus Pharma received regulatory clearance to initiate a randomized Phase 2b trial of its GnRH antagonist Teverelix in metastatic prostate cancer. The study will assess efficacy and safety across multiple dosing cohorts with patient enrollment expected to begin within weeks.
1. Regulatory Clearance
Medicus Pharma has obtained regulatory clearance to launch its randomized Phase 2b study of Teverelix in patients with metastatic prostate cancer, marking a key mid-stage development milestone.
2. Trial Design
The multicenter study will evaluate safety and efficacy across multiple dosing cohorts, measuring outcomes such as PSA reduction and progression-free survival over a defined treatment period.
3. Next Steps
Following clearance, Medicus Pharma plans to begin patient dosing within weeks and aims to generate interim safety data before year-end to inform a potential Phase 3 development plan.